TP53 and colon carcinoma: In this study, we show that at least additive cytotoxicity can be achieved by combined treatment of XR5944 with 5-FU or irinotecan (CPT-11), in two human colon carcinoma cell lines (HT29 and HCT116), differing in p53 status and sensitivity to chemotherapeutic drugs.